Review



recombinant sars cov 2 spike protein nanoparticle vaccine  (Novavax Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Novavax Inc recombinant sars cov 2 spike protein nanoparticle vaccine
    Recombinant Sars Cov 2 Spike Protein Nanoparticle Vaccine, supplied by Novavax Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+sars+cov+2+spike+protein+nanoparticle+vaccine/protein+subunit+vaccines/pm42107283-36-2-10
    Average 86 stars, based on 1 article reviews
    recombinant sars cov 2 spike protein nanoparticle vaccine - by Bioz Stars, 2026-10
    86/100 stars

    Images

    Related Articles

    Recombinant:

    Article Title: CD25 + cell depletion enhances protective immunity of PR8 inactivated influenza vaccine in aged mice.
    Article Snippet: Immunosenescence is a real biological process that leads to a quantitatively and qualitatively weaker immune response to vaccines in the aged population.. The adaptive immune system, especially B cells and T cells, is responsible for creating targeted, long-lasting immune memory and is the component most directly responsible for vaccine efficacy.. However, this system undergoes substantial functional decline with aging.



    Similar Products

    recombinant sars cov 2 spike protein nanoparticle vaccine  (Novavax Inc)
    86
    Novavax Inc recombinant sars cov 2 spike protein nanoparticle vaccine
    Recombinant Sars Cov 2 Spike Protein Nanoparticle Vaccine, supplied by Novavax Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+sars+cov+2+spike+protein+nanoparticle+vaccine/protein+subunit+vaccines/pm42107283-36-2-10
    Average 86 stars, based on 1 article reviews
    recombinant sars cov 2 spike protein nanoparticle vaccine - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    sars-cov-2 recombinant spike protein nanoparticle vaccine (sars-cov-2 rs) with matrix-m1tm adjuvant  (Novavax Inc)
    90
    Novavax Inc sars-cov-2 recombinant spike protein nanoparticle vaccine (sars-cov-2 rs) with matrix-m1tm adjuvant
    Sars Cov 2 Recombinant Spike Protein Nanoparticle Vaccine (Sars Cov 2 Rs) With Matrix M1tm Adjuvant, supplied by Novavax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+sars+cov+2+spike+protein+nanoparticle+vaccine/sars+cov+2+rs+matrix+m1+adjuvant/pmc10536880__NIHMS1927823___supplement___Supplement_2_Trial_Protocol_and_Statistical_Analysis_Plan-4-43-65
    Average 90 stars, based on 1 article reviews
    sars-cov-2 recombinant spike protein nanoparticle vaccine (sars-cov-2 rs) with matrix-m1tm adjuvant - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    sars-cov-2 recombinant spike protein nanoparticle vaccine  (Novavax Inc)
    90
    Novavax Inc sars-cov-2 recombinant spike protein nanoparticle vaccine
    Annual trends and topics of global publications. (A) Annual publications and the fitting equation for annual publications. The trend of annual publications is fitted using the exponential trendline type in Excel, where a higher R² value indicates a more precise alignment between the regression line and observed values. (B) Term contributions in nanovaccine research from 2020 to 2023. The terms were extracted from the title and abstract. Each node symbolizes a term, with the node’s dimensions mirroring its overall frequency. The color designates the frequency of each term in the period from 2020 to 2023 relative to its overall frequency. The proportion associated with each color is depicted at the bottom right of the figure. The closer the color is to red, the higher the proportion. For example, “lipid <t>nanoparticle”</t> appeared 128 times from 1981 to 2023, with 111 occurrences between 2020 and 2023, constituting 86.72%, and is therefore shown in red on the graph. The interpretation of this graph can be enhanced by considering both the size and color of the nodes: the larger and redder the node, the more prominent the term was as a research focus from 2020 to 2023. The detailed methodology is provided in <xref ref-type= Supplementary Material 1 .. " width="250" height="auto" />
    Sars Cov 2 Recombinant Spike Protein Nanoparticle Vaccine, supplied by Novavax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+sars+cov+2+spike+protein+nanoparticle+vaccine/sars+cov+2+rs/pmc11345159-30-0-19
    Average 90 stars, based on 1 article reviews
    sars-cov-2 recombinant spike protein nanoparticle vaccine - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    sars-cov-2 recombinant spike (s) protein nanoparticle vaccine  (Novavax Inc)
    90
    Novavax Inc sars-cov-2 recombinant spike (s) protein nanoparticle vaccine
    Annual trends and topics of global publications. (A) Annual publications and the fitting equation for annual publications. The trend of annual publications is fitted using the exponential trendline type in Excel, where a higher R² value indicates a more precise alignment between the regression line and observed values. (B) Term contributions in nanovaccine research from 2020 to 2023. The terms were extracted from the title and abstract. Each node symbolizes a term, with the node’s dimensions mirroring its overall frequency. The color designates the frequency of each term in the period from 2020 to 2023 relative to its overall frequency. The proportion associated with each color is depicted at the bottom right of the figure. The closer the color is to red, the higher the proportion. For example, “lipid <t>nanoparticle”</t> appeared 128 times from 1981 to 2023, with 111 occurrences between 2020 and 2023, constituting 86.72%, and is therefore shown in red on the graph. The interpretation of this graph can be enhanced by considering both the size and color of the nodes: the larger and redder the node, the more prominent the term was as a research focus from 2020 to 2023. The detailed methodology is provided in <xref ref-type= Supplementary Material 1 .. " width="250" height="auto" />
    Sars Cov 2 Recombinant Spike (S) Protein Nanoparticle Vaccine, supplied by Novavax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+sars+cov+2+spike+protein+nanoparticle+vaccine/sars+cov+2+rs+matrix+m1+adjuvant/pm38305154-39-3-0
    Average 90 stars, based on 1 article reviews
    sars-cov-2 recombinant spike (s) protein nanoparticle vaccine - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    sars-cov-2 recombinant spike protein nanoparticle (sars-cov-2 rs) (nvx-cov2373) vaccine  (Novavax Inc)
    90
    Novavax Inc sars-cov-2 recombinant spike protein nanoparticle (sars-cov-2 rs) (nvx-cov2373) vaccine
    Annual trends and topics of global publications. (A) Annual publications and the fitting equation for annual publications. The trend of annual publications is fitted using the exponential trendline type in Excel, where a higher R² value indicates a more precise alignment between the regression line and observed values. (B) Term contributions in nanovaccine research from 2020 to 2023. The terms were extracted from the title and abstract. Each node symbolizes a term, with the node’s dimensions mirroring its overall frequency. The color designates the frequency of each term in the period from 2020 to 2023 relative to its overall frequency. The proportion associated with each color is depicted at the bottom right of the figure. The closer the color is to red, the higher the proportion. For example, “lipid <t>nanoparticle”</t> appeared 128 times from 1981 to 2023, with 111 occurrences between 2020 and 2023, constituting 86.72%, and is therefore shown in red on the graph. The interpretation of this graph can be enhanced by considering both the size and color of the nodes: the larger and redder the node, the more prominent the term was as a research focus from 2020 to 2023. The detailed methodology is provided in <xref ref-type= Supplementary Material 1 .. " width="250" height="auto" />
    Sars Cov 2 Recombinant Spike Protein Nanoparticle (Sars Cov 2 Rs) (Nvx Cov2373) Vaccine, supplied by Novavax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+sars+cov+2+spike+protein+nanoparticle+vaccine/nvx+cov2373/pmc10547846__41598_2023_43578_MOESM2_ESM-133-12-0
    Average 90 stars, based on 1 article reviews
    sars-cov-2 recombinant spike protein nanoparticle (sars-cov-2 rs) (nvx-cov2373) vaccine - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    sii-nvx-cov2373 (sars-cov-2 recombinant spike protein nanoparticle vaccine matrix-m™ adjuvant  (Serum Institute India)
    90
    Serum Institute India sii-nvx-cov2373 (sars-cov-2 recombinant spike protein nanoparticle vaccine matrix-m™ adjuvant
    Demographics and baseline characteristics - safety population.
    Sii Nvx Cov2373 (Sars Cov 2 Recombinant Spike Protein Nanoparticle Vaccine Matrix M™ Adjuvant, supplied by Serum Institute India, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+sars+cov+2+spike+protein+nanoparticle+vaccine/nvx+cov2373+covovax/pmc10547846-92-0-10
    Average 90 stars, based on 1 article reviews
    sii-nvx-cov2373 (sars-cov-2 recombinant spike protein nanoparticle vaccine matrix-m™ adjuvant - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    nvx-cov2373 recombinant sars-cov-2 spike protein nanoparticle vaccine with matrix m adjuvant  (Novavax Inc)
    90
    Novavax Inc nvx-cov2373 recombinant sars-cov-2 spike protein nanoparticle vaccine with matrix m adjuvant
    Demographics and baseline characteristics - safety population.
    Nvx Cov2373 Recombinant Sars Cov 2 Spike Protein Nanoparticle Vaccine With Matrix M Adjuvant, supplied by Novavax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+sars+cov+2+spike+protein+nanoparticle+vaccine/nvx+cov2373/pmc10433199-448-18-9
    Average 90 stars, based on 1 article reviews
    nvx-cov2373 recombinant sars-cov-2 spike protein nanoparticle vaccine with matrix m adjuvant - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Annual trends and topics of global publications. (A) Annual publications and the fitting equation for annual publications. The trend of annual publications is fitted using the exponential trendline type in Excel, where a higher R² value indicates a more precise alignment between the regression line and observed values. (B) Term contributions in nanovaccine research from 2020 to 2023. The terms were extracted from the title and abstract. Each node symbolizes a term, with the node’s dimensions mirroring its overall frequency. The color designates the frequency of each term in the period from 2020 to 2023 relative to its overall frequency. The proportion associated with each color is depicted at the bottom right of the figure. The closer the color is to red, the higher the proportion. For example, “lipid nanoparticle” appeared 128 times from 1981 to 2023, with 111 occurrences between 2020 and 2023, constituting 86.72%, and is therefore shown in red on the graph. The interpretation of this graph can be enhanced by considering both the size and color of the nodes: the larger and redder the node, the more prominent the term was as a research focus from 2020 to 2023. The detailed methodology is provided in <xref ref-type= Supplementary Material 1 .. " width="100%" height="100%">

    Journal: Frontiers in Immunology

    Article Title: A bibliometric insight into nanomaterials in vaccine: trends, collaborations, and future avenues

    doi: 10.3389/fimmu.2024.1420216

    Figure Lengend Snippet: Annual trends and topics of global publications. (A) Annual publications and the fitting equation for annual publications. The trend of annual publications is fitted using the exponential trendline type in Excel, where a higher R² value indicates a more precise alignment between the regression line and observed values. (B) Term contributions in nanovaccine research from 2020 to 2023. The terms were extracted from the title and abstract. Each node symbolizes a term, with the node’s dimensions mirroring its overall frequency. The color designates the frequency of each term in the period from 2020 to 2023 relative to its overall frequency. The proportion associated with each color is depicted at the bottom right of the figure. The closer the color is to red, the higher the proportion. For example, “lipid nanoparticle” appeared 128 times from 1981 to 2023, with 111 occurrences between 2020 and 2023, constituting 86.72%, and is therefore shown in red on the graph. The interpretation of this graph can be enhanced by considering both the size and color of the nodes: the larger and redder the node, the more prominent the term was as a research focus from 2020 to 2023. The detailed methodology is provided in Supplementary Material 1 ..

    Article Snippet: Phase 1-2 trial of a sars-cov-2 recombinant spike protein nanoparticle vaccine , 2020 , 701 , Keech, C , Novavax , USA , New England Journal of Medicine.

    Techniques:

    Information on the top 7 clusters in the co-cited authors’ network.

    Journal: Frontiers in Immunology

    Article Title: A bibliometric insight into nanomaterials in vaccine: trends, collaborations, and future avenues

    doi: 10.3389/fimmu.2024.1420216

    Figure Lengend Snippet: Information on the top 7 clusters in the co-cited authors’ network.

    Article Snippet: Phase 1-2 trial of a sars-cov-2 recombinant spike protein nanoparticle vaccine , 2020 , 701 , Keech, C , Novavax , USA , New England Journal of Medicine.

    Techniques:

    The top 20 publications in number of total citations.

    Journal: Frontiers in Immunology

    Article Title: A bibliometric insight into nanomaterials in vaccine: trends, collaborations, and future avenues

    doi: 10.3389/fimmu.2024.1420216

    Figure Lengend Snippet: The top 20 publications in number of total citations.

    Article Snippet: Phase 1-2 trial of a sars-cov-2 recombinant spike protein nanoparticle vaccine , 2020 , 701 , Keech, C , Novavax , USA , New England Journal of Medicine.

    Techniques: Activation Assay, Vaccines, Membrane, Recombinant, Blocking Assay, Immunopeptidomics, In Vitro, In Vivo, Liposomes, Adjuvant, Modification, Bioprocessing, Infection, Molecular Weight

    The top 10 co-cited references in #2, #3, and #5 clusters.

    Journal: Frontiers in Immunology

    Article Title: A bibliometric insight into nanomaterials in vaccine: trends, collaborations, and future avenues

    doi: 10.3389/fimmu.2024.1420216

    Figure Lengend Snippet: The top 10 co-cited references in #2, #3, and #5 clusters.

    Article Snippet: Phase 1-2 trial of a sars-cov-2 recombinant spike protein nanoparticle vaccine , 2020 , 701 , Keech, C , Novavax , USA , New England Journal of Medicine.

    Techniques: Vaccines, In Vivo, Polymer, Immunopeptidomics, Membrane, Adjuvant, Modification, Virus, Binding Assay, Bioprocessing, Infection

    Top ten co-cited references in nanovaccine research.

    Journal: Frontiers in Immunology

    Article Title: A bibliometric insight into nanomaterials in vaccine: trends, collaborations, and future avenues

    doi: 10.3389/fimmu.2024.1420216

    Figure Lengend Snippet: Top ten co-cited references in nanovaccine research.

    Article Snippet: Phase 1-2 trial of a sars-cov-2 recombinant spike protein nanoparticle vaccine , 2020 , 701 , Keech, C , Novavax , USA , New England Journal of Medicine.

    Techniques: Vaccines, Drug discovery

    Demographics and baseline characteristics - safety population.

    Journal: Scientific Reports

    Article Title: A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults

    doi: 10.1038/s41598-023-43578-w

    Figure Lengend Snippet: Demographics and baseline characteristics - safety population.

    Article Snippet: SII-NVX-CoV2373 (SARS-CoV-2 recombinant spike protein nanoparticle vaccine with Matrix-M™ adjuvant, Serum Institute of India Pvt.

    Techniques:

    Non-inferiority of SII-NVX-CoV2373 heterologous booster to homologous booster in terms for Anti-S IgG and neutralizing antibodies at Visit 2-Day 29 - Per Protocol Population.

    Journal: Scientific Reports

    Article Title: A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults

    doi: 10.1038/s41598-023-43578-w

    Figure Lengend Snippet: Non-inferiority of SII-NVX-CoV2373 heterologous booster to homologous booster in terms for Anti-S IgG and neutralizing antibodies at Visit 2-Day 29 - Per Protocol Population.

    Article Snippet: SII-NVX-CoV2373 (SARS-CoV-2 recombinant spike protein nanoparticle vaccine with Matrix-M™ adjuvant, Serum Institute of India Pvt.

    Techniques:

    Summary of solicited adverse events safety population.

    Journal: Scientific Reports

    Article Title: A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults

    doi: 10.1038/s41598-023-43578-w

    Figure Lengend Snippet: Summary of solicited adverse events safety population.

    Article Snippet: SII-NVX-CoV2373 (SARS-CoV-2 recombinant spike protein nanoparticle vaccine with Matrix-M™ adjuvant, Serum Institute of India Pvt.

    Techniques: Injection